Infinity Pharmaceuticals, Inc., a biopharmaceutical company, develops medicines for people with cancer in the United States. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma (PI3K-gamma), which is in Phase 1/1b clinical study. The company has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib, as well as duvelisib program, including DUO study that is in randomized and monotherapy Phase III clinical study for patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma; PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate; and AbbVie Inc. to develop and commercialize products containing duvelisib in oncology indications., as well as collaboration agreement with Arcus Biosciences, Inc. Infinity Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:INFI
CUSIP45665G30
Phone617-453-1000
Debt
Debt-to-Equity RatioN/A
Current Ratio8.89
Quick Ratio8.89
Price-To-Earnings
Trailing P/E Ratio-2.33
Forward P/E Ratio-3.57
P/E GrowthN/A
Sales & Book Value
Annual Sales$6 million
Price / Sales18.29
Cash FlowN/A
Price / CashN/A
Book Value$0.94 per share
Price / Book2.05
Profitability
EPS (Most Recent Fiscal Year)($0.83)
Net Income$-41,830,000.00
Net MarginsN/A
Return on Equity-64.18%
Return on Assets-54.82%
Miscellaneous
Employees22
Outstanding Shares56,850,000
Market Cap$119.96 million
Infinity Pharmaceuticals (NASDAQ:INFI) Frequently Asked Questions
What is Infinity Pharmaceuticals' stock symbol?
Infinity Pharmaceuticals trades on the NASDAQ under the ticker symbol "INFI."
How were Infinity Pharmaceuticals' earnings last quarter?
Infinity Pharmaceuticals Inc. (NASDAQ:INFI) posted its quarterly earnings results on Tuesday, August, 7th. The biotechnology company reported ($0.12) EPS for the quarter, topping the Zacks' consensus estimate of ($0.20) by $0.08. View Infinity Pharmaceuticals' Earnings History.
When is Infinity Pharmaceuticals' next earnings date?
What price target have analysts set for INFI?
2 brokers have issued 1 year price objectives for Infinity Pharmaceuticals' shares. Their predictions range from $4.00 to $4.00. On average, they anticipate Infinity Pharmaceuticals' stock price to reach $4.00 in the next twelve months. This suggests a possible upside of 107.3% from the stock's current price. View Analyst Price Targets for Infinity Pharmaceuticals.
What is the consensus analysts' recommendation for Infinity Pharmaceuticals?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Infinity Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Infinity Pharmaceuticals.
Who are some of Infinity Pharmaceuticals' key competitors?
Some companies that are related to Infinity Pharmaceuticals include Unum Therapeutics (UMRX), Rigel Pharmaceuticals (RIGL), Depomed (DEPO), Akebia Therapeutics (AKBA), Forty Seven (FTSV), Aurinia Pharmaceuticals (AUPH), Zymeworks (ZYME), Stemline Therapeutics (STML), Aduro BioTech (ADRO), Synergy Pharmaceuticals (SGYP), Magenta Therapeutics (MGTA), Merus (MRUS), ZEALAND PHARMA/S (ZEAL), ZIOPHARM Oncology (ZIOP) and Dermira (DERM).
Who are Infinity Pharmaceuticals' key executives?
Infinity Pharmaceuticals' management team includes the folowing people:
- Ms. Adelene Q. Perkins, Chairman & CEO (Age 58)
- Dr. Lawrence E. Bloch, Pres & Treasurer (Age 52)
- Dr. Jeffery L. Kutok, Sr. VP & Chief Scientific Officer (Age 51)
- Mr. Seth A. Tasker, VP, Gen. Counsel & Sec. (Age 39)
- Ms. Melissa Hackel, VP of Fin.
Has Infinity Pharmaceuticals been receiving favorable news coverage?
News stories about INFI stock have been trending somewhat positive this week, Accern Sentiment reports. Accern identifies negative and positive media coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Infinity Pharmaceuticals earned a daily sentiment score of 0.11 on Accern's scale. They also gave media headlines about the biotechnology company an impact score of 45.59 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the next several days. View Recent Headlines for Infinity Pharmaceuticals.
Who are Infinity Pharmaceuticals' major shareholders?
Infinity Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include Platinum Investment Management Ltd. (1.99%), Dimensional Fund Advisors LP (1.66%), Acadian Asset Management LLC (0.66%), Essex Investment Management Co. LLC (0.29%) and Algert Global LLC (0.13%). Company insiders that own Infinity Pharmaceuticals stock include Adelene Q Perkins, Bvf Partners L P/Il, Jeffery Kutok, Lawrence E Bloch, Michael C Venuti, Sujay Kango and Value Fund L P Biotechnology. View Institutional Ownership Trends for Infinity Pharmaceuticals.
Which major investors are selling Infinity Pharmaceuticals stock?
INFI stock was sold by a variety of institutional investors in the last quarter, including Platinum Investment Management Ltd.. Company insiders that have sold Infinity Pharmaceuticals company stock in the last year include Adelene Q Perkins and Jeffery Kutok. View Insider Buying and Selling for Infinity Pharmaceuticals.
Which major investors are buying Infinity Pharmaceuticals stock?
INFI stock was bought by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP, Acadian Asset Management LLC, Essex Investment Management Co. LLC and Algert Global LLC. Company insiders that have bought Infinity Pharmaceuticals stock in the last two years include Bvf Partners L P/Il, Lawrence E Bloch and Value Fund L P Biotechnology. View Insider Buying and Selling for Infinity Pharmaceuticals.
How do I buy shares of Infinity Pharmaceuticals?
Shares of INFI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Infinity Pharmaceuticals' stock price today?
One share of INFI stock can currently be purchased for approximately $1.93.
How big of a company is Infinity Pharmaceuticals?
Infinity Pharmaceuticals has a market capitalization of $119.96 million and generates $6 million in revenue each year. The biotechnology company earns $-41,830,000.00 in net income (profit) each year or ($0.83) on an earnings per share basis. Infinity Pharmaceuticals employs 22 workers across the globe.
How can I contact Infinity Pharmaceuticals?
Infinity Pharmaceuticals' mailing address is 784 MEMORIAL DRIVE, CAMBRIDGE MA, 02139. The biotechnology company can be reached via phone at 617-453-1000 or via email at [email protected]
MarketBeat Community Rating for Infinity Pharmaceuticals (NASDAQ INFI)
MarketBeat's community ratings are surveys of what our community members think about Infinity Pharmaceuticals and other stocks. Vote "Outperform" if you believe INFI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe INFI will underperform the S&P 500 over the long term. You may vote once every thirty days.
